Sanofi's Dupixent Becomes First Biologic Approved in the US for COPD With Eosinophilic Phenotype
Sep 28, 2024
Dupixent Investment Portfolios
Sanofi's Dupixent Shows Promise for Young EoE Patients in Phase 3 Trials
Jun 27, 2024